Item(by='philipn', descendants=None, kids=None, score=None, time=1604715076, title=None, item_type='comment', url=None, parent=25008493, text='Yes, this is one reason why an approach using a form of soluble ACE2 is so promising; mutations that would normally cause e.g. monoclonal antibodies to stop working (as detailed with the mink mutation) would in theory <i>not</i> stop the &#x27;decoy receptor&#x27; approach.<p>Despite the fact soluble ACE2 is not looking like it&#x27;ll be developed in time to impact the pandemic, there is a silver lining:<p>If you look at the original paper (<a href="https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lanres&#x2F;article&#x2F;PIIS2213-2600(20)30418-5&#x2F;fulltext" rel="nofollow">https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lanres&#x2F;article&#x2F;PIIS2213-2...</a>), you&#x27;ll note they include details on angiotensin peptide levels in the patient.<p>If improvement in these angiotensin peptides with soluble ACE2 therapy led to clinical improvements, then it&#x27;s likely many of these same improvements would be possible using a common class of widely-available blood pressure medications called ARBs.<p>This approach would not neutralize the virus, but instead stop the body from damaging itself.  That&#x27;s the theory, at least.<p>There are ~20 trials of ARBs for COVID-19 in progress now, though almost all are underdosed.')